Date published: 2026-4-28

1-800-457-3801

SCBT Portrait Logo
Seach Input

TRAP220 Inhibitors

TRAP220 inhibitors belong to a distinctive chemical class of compounds that have garnered significant attention within the realm of molecular research. These inhibitors specifically target the Transcriptional Adaptor 220 (TRAP220) protein, a crucial component of various transcriptional complexes responsible for regulating gene expression. TRAP220, also known as PPARBP or MED1, serves as a coactivator in transcriptional processes, facilitating the interaction between transcription factors and the RNA polymerase II complex. It plays a pivotal role in gene transcription related to a wide array of cellular functions, including development, metabolism, and cell differentiation.

TRAP220 inhibitors are meticulously designed molecules that function by impeding the interaction between TRAP220 and its binding partners, thereby hindering the coactivation of gene transcription. These inhibitors act as potent modulators of gene expression, allowing researchers to delve deeper into the intricate mechanisms underlying various biological processes. By selectively targeting the TRAP220 protein, these inhibitors offer a valuable tool for deciphering the complexities of transcriptional regulation and its impact on cellular functions. Moreover, the development of TRAP220 inhibitors opens up new avenues for exploring applications in molecular biology research and enhancing our understanding of gene expression networks.

SEE ALSO...

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

Inhibits epidermal growth factor receptor (EGFR) tyrosine kinase activity, disrupting downstream signaling pathways.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Targets and inhibits BCR-ABL tyrosine kinase, used for chronic myeloid leukemia (CML) and other cancers.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Multikinase inhibitor; interrupts RAF/MEK/ERK signaling and VEGFR/PDGFR tyrosine kinases in cancer cells.

Lapatinib

231277-92-2sc-353658
100 mg
$420.00
32
(1)

Dual HER2 and EGFR inhibitor, hindering cell growth and proliferation in HER2-positive breast cancer.

Dasatinib

302962-49-8sc-358114
sc-358114A
25 mg
1 g
$70.00
$145.00
51
(1)

Targets multiple tyrosine kinases including BCR-ABL, SRC family kinases; used in CML and acute lymphoblastic leukemia.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$117.00
$423.00
11
(1)

Specifically inhibits mutated BRAF kinase in melanomas with the V600E mutation, attenuating MAPK pathway activation.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

Blocks CDK4/6, halting cell cycle progression, and used in combination with endocrine therapy in hormone receptor-positive breast cancer.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$251.00
$500.00
$547.00
16
(1)

Selective JAK1/JAK2 inhibitor; modulates cytokine signaling and used for myelofibrosis and polycythemia vera.

CH5424802

1256580-46-7sc-364461
sc-364461A
5 mg
50 mg
$191.00
$902.00
(0)

Targets ALK kinase and inhibits ALK-dependent tumor growth, approved for ALK-positive non-small cell lung cancer.

Ibrutinib

936563-96-1sc-483194
10 mg
$156.00
5
(0)

Irreversibly inhibits BTK, a key mediator in B-cell signaling; used for B-cell malignancies like CLL and lymphomas.